- Home
- MNOV vs NEPH Comparison
MNOV vs NEPH Comparison
Compare MNOV & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- NEPH
- Stock Information
- Founded
- MNOV 2000
- NEPH 1997
- Country
- MNOV United States
- NEPH United States
- Employees
- MNOV N/A
- NEPH N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- NEPH Medical/Dental Instruments
- Sector
- MNOV Health Care
- NEPH Health Care
- Exchange
- MNOV Nasdaq
- NEPH Nasdaq
- Market Cap
- MNOV 65.7M
- NEPH 57.2M
- IPO Year
- MNOV 2005
- NEPH 2004
- Fundamental
- Price
- MNOV $1.22
- NEPH $5.26
- Analyst Decision
- MNOV Strong Buy
- NEPH Strong Buy
- Analyst Count
- MNOV 2
- NEPH 2
- Target Price
- MNOV $7.00
- NEPH $5.50
- AVG Volume (30 Days)
- MNOV 24.9K
- NEPH 72.5K
- Earning Date
- MNOV 11-12-2025
- NEPH 11-06-2025
- Dividend Yield
- MNOV N/A
- NEPH N/A
- EPS Growth
- MNOV N/A
- NEPH N/A
- EPS
- MNOV N/A
- NEPH 0.12
- Revenue
- MNOV $134,599.00
- NEPH $16,684,000.00
- Revenue This Year
- MNOV N/A
- NEPH $24.38
- Revenue Next Year
- MNOV N/A
- NEPH $10.16
- P/E Ratio
- MNOV N/A
- NEPH $41.03
- Revenue Growth
- MNOV N/A
- NEPH 21.16
- 52 Week Low
- MNOV $1.13
- NEPH $1.36
- 52 Week High
- MNOV $2.55
- NEPH $5.98
- Technical
- Relative Strength Index (RSI)
- MNOV 41.14
- NEPH 56.83
- Support Level
- MNOV $1.23
- NEPH $4.77
- Resistance Level
- MNOV $1.26
- NEPH $5.74
- Average True Range (ATR)
- MNOV 0.03
- NEPH 0.52
- MACD
- MNOV -0.00
- NEPH -0.02
- Stochastic Oscillator
- MNOV 16.67
- NEPH 49.54
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.